Making history! We're proud to be the first Korean pharmaceutical company to list on NASDAQ and looking forward to embarking on phase 3 clinical trial of PM-012 for the treatment of dementia and Alzheimer’s disease with the FDA. Our goal is to make sure
Aducanumab, the latest drug approved by the FDA for the treatment of Alzheimer'sis estimated to cost $56,000 annually. According to the New York Times, "There’s little evidence that the drug, Aduhelm, slows the progression of dementia, but the Food and Dr
Brain One is a naturally derived supplement made from a combination of extracts to improve memory %26 concentration. Combining the natural compounds with four-year-aged Korean ginseng boosts the immune system, enhances platelet count, and increases blood
